Supplementary Materials

Alkoxy and Enediyne Derivatives Containing 1.4-Benzoquinone Subunits – Synthesis and Antitumor Activity

Monika Kadela-Tomanek, Ewa Bębenek, Elwira Chrobak, Małgorzata Latocha, Stanisław Boryczka

Table S1: The selectivity index (SI) value for Compounds 1-28 and cisplatin.

- **Table S2**: The parameters determined by computational methods such as lipophilicity (cLogP), molecular mass (M), number of donors (nHD) and acceptors (nHA) of hydrogen bonds, number of rotatable bonds (nRTB), topological polar surface area (PSA), and penetration drug by BBB (log BB).
- **Figure S1**: (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 2-chloro-3-(2-propenoxy)-1,4-naphthoquinon (5).
- Figure S2: (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 2-chloro-3-(2-propynoxy)-1,4-naphthoquinon (6).
- **Figure S3**: (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 6-chloro-2-methyl-7-propoxy-5,8-quinolinedione (**10**).
- **Figure S4:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 6-chloro-2-methyl-7-(2-propenoxy)-5,8-quinolinedione (**11**).
- **Figure S5:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 6chloro-2-methyl-7-(2-propynoxy)-5,8-quinolinedione (**12**).
- **Figure S6:** (a) ¹H NMR spectrum, (b) ¹³C NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 2,3-di(2-propenoxy)-1,4-naphthoquinon (14).
- **Figure S7:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 2,3-di(2-propynoxy)-1,4-naphthoquinon (**15**).
- **Figure S8:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 2-methyl-6,7-dipropoxy-5,8-quinolinedione (**19**).
- Figure S9: (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 2-methyl-6,7-di(2-propenoxy)-5,8-quinolinedione (20).
- **Figure S10:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 2-methyl-6,7-di(2-propynoxy)-5,8-qunolinedione (**21**).
- **Figure S11:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 2-chloro-3-(8-hydroxy-4-octen-2,6-diynyloxy)-1,4-naphtoquinon (**23**).
- Figure S12: (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-5,8-quinolinedione (24).
- Figure S13: (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum6chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-2-methyl-5,8-quinolinedione (25).
- **Figure S14:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-1,4-naphthoquinon (**26**).
- **Figure S15:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-5,8-quinolinedione (**27**).
- **Figure S16:** (a) ¹H-NMR spectrum, (b) ¹³C-NMR spectrum, (c) IR spectrum, (d) HR-MS spectrum of 8-octen-6,10-diynyl-1,4-8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-2-methyl-5,8-quinolinedione (**28**).

Comment	SI (IC50 HFF-1/IC50 cancer line)					
Compound	C-32	SNB-19	MDA-MB-231			
1	0.62	0.59	0.49			
2	0.69	0.60	0.63			
3	0.95	0.63	0.43			
4	0.88	0.80	10.57			
5	0.95	1.00	0.55			
6	1.22	0.46	0.19			
7	-	-	-			
8	-	-	-			
9	10.31	0.16	0.15			
10	0.59	0.80	0.71			
11	0.12	0.59	0.82			
12	0.07	0.72	0.81			
13	0.48	0.54	0.48			
14	0.42	0.22	0.25			
15	0.62	0.73	5.19			
16	-	-	-			
17	-	-	-			
18	50.40	0.58	7.00			
19	0.14	0.69	0.25			
20	0.03	0.04	0.02			
21	0.69	0.59	0.63			
22	1.64	1.04	1.85			
23	0.67	0.52	0.23			
24	-	-	-			
25	0.23	0.16	0.61			
26	0.58	0.77	0.11			
27	0.27	0.41	1.93			
28	0.18	0.18	6.25			
cisplatin	0.55	0.48	2.80			

Table S1: The selectivity index (SI) value for Compounds 1-28 and cisplatin.

Table S2: The parameters determined by computational methods such as lipophilicity (cLogP), molecular mass (M), number of donors (nHD) and acceptors (nHA) of hydrogen bonds, number of rotatable bonds (nRTB), topological polar surface area (PSA), and penetration drug by BBB (log BB).

Compound	Μ	clopP	nHA	nHD	nRTB	PSA	logBB
_	[g/mol]	_				[Ų]	_
1	227	2.55	2	0	0	34.14	- 0.45
2	242	2.69	3	0	0	47.03	- 0.61
3	227	2.17	3	0	0	47.03	- 0.25
4	250	2.33	3	0	3	43.38	- 0.36
5	248	2.59	3	0	3	43.38	- 0.16
6	246	2.21	3	0	2	43.38	- 0.71
7	266	2.41	4	0	3	56.27	- 0.42
8	264	2.29	4	0	3	56.27	- 0.14
9	263	1.75	4	0	2	56.27	- 0.85
10	251	1.95	4	0	3	56.27	- 0.19
11	249	1.57	4	0	3	56.27	- 0.04
12	247	1.15	4	0	2	56.27	- 0.76
13	275	2.57	4	0	6	52.61	- 0.06
14	271	2.28	4	0	6	52.61	- 0.06
15	266	1.77	4	0	4	52.61	- 1.25
16	290	2.20	5	0	6	65.50	- 0.21
17	287	1.84	5	0	6	65.50	- 0.10
18	284	1.49	5	0	4	65.50	- 1.27
19	278	2.06	5	0	6	65.50	- 0.06
20	271	1.84	5	0	6	65.50	- 0.06
21	367	1.02	5	0	4	65.50	- 1.16
22	136	1.01	2	2	0	40.46	- 0.57
23	326	3.20	4	1	2	63.60	- 0.54
24	328	2.57	5	1	2	76.50	- 0.83
25	342	2.23	5	1	2	76.50	- 0.69
26	291	3.23	4	0	0	52.61	- 0.41
27	292	2.45	5	0	0	65.50	- 0.70
28	306	2.15	5	0	0	65.50	- 0.57



Figure S1 (a): ¹H-NMR spectrum of 2-chloro-3-(2-propenoxy)-1,4-naphthoquinon (5).



Figure S1 (b): ¹³C-NMR spectrum of 2-chloro-3-(2-propenoxy)-1,4-naphthoquinon (5).



Figure S1 (c): IR spectrum of 2-chloro-3-(2-propenoxy)-1,4-naphthoquinon (5).



+MS, 0.0-0.4min #1-25







Figure S1 (d): HR-MS spectrum of 2-chloro-3-(2-propenoxy)-1,4-naphthoquinon (5).



Figure S2 (a): ¹H-NMR spectrum of 2-chloro-3-(2-propynoxy)-1,4-naphtoquinon (6).



Figure S2 (b): ¹³C-NMR spectrum of 2-chloro-3-(2-propynoxy)-1,4-naphtoquinon (6).



Figure S2 (c): HR-MS spectrum of 2-chloro-3-(2-propynoxy)-1,4-naphtoquinon (6).



+MS, 0.0-0.4min #1-25



mk6.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 11:26:37 AM

Page 1 of 1





Figure S3 (a): ¹H-NMR spectrum of 6-chloro-2-methyl-7-propoxy-5,8-quinolinedione (10).



Figure S3 (b): ¹³C-NMR spectrum of 6-chloro-2-methyl-7-propoxy-5,8-quinolinedione (10).



Figure S3 (c): IR spectrum of 6-chloro-2-methyl-7-propoxy-5,8-quinolinedione (10).



+MS, 0.0-0.3min #1-17





(d)

Figure S3 (d): HR-MS spectrum of 6-chloro-2-methyl-7-propoxy-5,8-quinolinedione (10).



Figure S4 (a): ¹H-NMR spectrum of 6-chloro-2-methyl-7-(2-propenoxy)-5,8-quinolinedione (11).



Figure S4 (b): ¹³C-NMR spectrum of 6-chloro-2-methyl-7-(2-propenoxy)-5,8-quinolinedione (11).



Figure S4 (c): IR spectrum of 6-chloro-2-methyl-7-(2-propenoxy)-5,8-quinolinedione (11).



+MS, 0.0-0.7min #1-43



mk11.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 11:32:37 AM

Page 1 of 1





Figure S5 (a): ¹H-NMR spectrum of 6-chloro-2-methyl-7-(2-propynoxy)-5,8-quinolinedione (12).



Figure S5 (b): ¹³C-NMR spectrum of 6-chloro-2-methyl-7-(2-propynoxy)-5,8-quinolinedione (12).



Figure S5 (c): IR spectrum of 6-chloro-2-methyl-7-(2-propynoxy)-5,8-quinolinedione (12).



+MS, 0.0-0.5min #1-27



mk12.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 11:34:52 AM

Page 1 of 1





Figure S6 (a): ¹³C-NMR spectrum of 2,3-di(2-propenoxy)-1,4-naphtoquinon (14).



Figure S6 (b): ¹H-NMR spectrum of 2,3-di(2-propenoxy)-1,4-naphtoquinon (**14**).



Figure S6 (c): IR spectrum of 2,3-di(2-propenoxy)-1,4-naphtoquinon (14).



+MS, 0.0-0.5min #1-30



mk14b.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 12:12:10 PM

Page 1 of 1





Figure S7 (a): ¹H-NMR spectrum of 2,3-di(2-propynoxy)-1,4-naphthoquinon (15).



Figure S7 (b): ¹³C-NMR spectrum of 2,3-di(2-propynoxy)-1,4-naphthoquinon (15).



Figure S7 (c): IR spectrum of 2,3-di(2-propynoxy)-1,4-naphthoquinon (15).



+MS, 0.0-0.5min #1-30



mk15b.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 12:20:30 PM

Page 1 of 1





Figure S8 (a): ¹H-NMR spectrum of 2-methyl-6,7-dipropoxy-5,8-quinolinedione (19).



Figure S8 (b): ¹³C-NMR spectrum of 2-methyl-6,7-dipropoxy-5,8-quinolinedione (**19**).



Figure S8 (c): IR spectrum of 2-methyl-6,7-dipropoxy-5,8-quinolinedione (19).

Analysis Info				Acquisition D	ate 2/17/201	17 11:46:11 AM
Analysis Name Method Sample Name Comment	D:\Data\mk19.d low_mass.m TM Low concentratio	'n		Operator Instrument	KM impact II	1825265.10082
Acquisition Pa	rameter					
Source Type Focus Scan Begin Scan End	ESI Active 100 m/z 1000 m/z	lon Polarity Set Capillary Set End Plate O Set Charging Vo Set Corona	Positive 4000 V ffset -500 V oltage 2000 V 0 nA	Set Set Set Set Set	Nebulizer Dry Heater Dry Gas Divert Valve APCI Heater	0.3 Bar 240 °C 4.0 l/min Source 0 °C
Intens. x107 1.400 1.375 1.350 1.325 1.300						
1.275	0.10 0.15	5 0.20	0.25 0.30	0.35 0.4	0 0.45	Time [min]

+MS, 0.0-0.5min #1-32



mk19.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 11:47:15 AM

Page 1 of 1

Figure S8 (d): HR-MS spectrum of 2-methyl-6,7-dipropoxy-5,8-quinolinedione (19).



Figure S9 (a): ¹H-NMR spectrum of 2-methyl-6,7-di(2-propenoxy)-5,8-quinolinedione (20).



Figure S9 (b): ¹³C-NMR spectrum of 2-methyl-6,7-di(2-propenoxy)-5,8-quinolinedione (20).



Figure S9 (c): IR spectrum of 2-methyl-6,7-di(2-propenoxy)-5,8-quinolinedione (20).



+MS, 0.0-0.5min #1-29



mk20.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 11:50:25 AM

by: KM

Page 1 of 1

Figure S9 (d): HR-MS spectrum of 2-methyl-6,7-di(2-propenoxy)-5,8-quinolinedione (20).



Figure S10 (a): ¹H-NMR spectrum of 2-methyl-6,7-di(2-propynoxy)-5,8-qunolinedione (21).



Figure S10 (b): ¹³C-NMR spectrum of 2-methyl-6,7-di(2-propynoxy)-5,8-qunolinedione (21).



Figure S10 (c): IR spectrum of 2-methyl-6,7-di(2-propynoxy)-5,8-qunolinedione (21).

Analysis Info				Acquisition Date 2/17/201	7 11:51:42 AM
Analysis Name Method Sample Name Comment	D:\Data\mk21.d low_mass.m TM Low concentration			Operator KM Instrument impact II	1825265.10082
Acquisition Par	ameter				
Source Type Focus Scan Begin Scan End	ESI Active 100 m/z 1000 m/z	lon Polarity Set Capillary Set End Plate Offset Set Charging Voltage Set Corona	Positive 4000 V -500 V 2000 V 0 nA	Set Nebulizer Set Dry Heater Set Dry Gas Set Divert Valve Set APCI Heater	0.3 Bar 240 °C 4.0 l/min Source 0 °C
Intens. x107 1.85 1.80 1.75 1.70 1.65 1.60	0,1		0.3		.5 Time [min]

+MS, 0.0-0.6min #1-34



mk21.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 11:52:45 AM

by: KM

Page 1 of 1





Figure S11 (a): ¹³C-NMR spectrum of 2-chloro-3-(8-hydroxy-4-octen-2,6-diynyloxy)-1,4-naphtoquinon (23).



Figure S11 (b): ¹³C-NMR spectrum of 2-chloro-3-(8-hydroxy-4-octen-2,6-diynyloxy)-1,4-naphtoquinon (23).



Figure S11 (c): IR spectrum of 2-chloro-3-(8-hydroxy-4-octen-2,6-diynyloxy)-1,4-naphtoquinon (23).



+MS, 0.0-0.5min #1-30



mk23.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 11:55:30 AM

Page 1 of 1

Figure S11 (d): HR-MS spectrum of 2-chloro-3-(8-hydroxy-4-octen-2,6-diynyloxy)-1,4-naphtoquinon (23).



Figure S12 (a): ¹H-NMR spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-5,8-quinolinedione (24).



Figure S12 (b): ¹H-NMR spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-5,8-quinolinedione (24).



Figure S12 (c): IR spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-5,8-quinolinedione (24).



+MS, 0.0-0.6min #1-34



mk24.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 11:57:50 AM

by: KM

Page 1 of 1

Figure S12 (d): HR-MS spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-5,8-quinolinedione (24).



Figure S13 (a): ¹H-NMR spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-2-methyl-5,8-quinolinedione (25).



Figure S13 (b): ¹³C-NMR spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-2-methyl-5,8-quinolinedione (25).



Figure S13 (c): IR spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-2-methyl-5,8-quinolinedione (25).



+MS, 0.0-0.5min #1-32



mk25.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 12:01:44 PM

by: KM

Page 1 of 1

Figure S13 (d): HR-MS spectrum of 6-chloro-7-(8-hydroxy-4-octen-2,6-diynyloxy)-2-methyl-5,8quinolinedione (**25**).



Figure S14 (a): ¹H-NMR spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-1,4-naphthoquinon (26).



Figure S14 (b): ¹³C-NMR spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-1,4-naphthoquinon (26).



Figure S14 (c): IR spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-1,4-naphthoquinon (26).



+MS, 0.0-0.5min #1-30



mk26.d Bruker Compass DataAnalysis 4.3 printed: 2/17/2017 12:04:38 PM

by: KM

Page 1 of 1

Figure S14 (d): HR-MS spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-1,4naphthoquinon (26).



Figure S15 (a): ¹³C-NMR spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-5,8-quinolinedione (27).



Figure S15 (b): ¹H-NMR spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-5,8-quinolinedione (27).



Figure S15 (c): IR spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-5,8-quinolinedione (27).

Analysis Info				Acquisition	Date 2/17/201	17 12:06:09 PM
Analysis Name Method Sample Name Comment	D:\Data\mk27.d low_mass.m TM Low concentration			Operator Instrument	KM impact II	1825265.10082
Acquisition Par	rameter					
Source Type Focus Scan Begin Scan End	ESI Active 100 m/z 1000 m/z	Ion Polarity Set Capillary Set End Plate Offset Set Charging Voltage Set Corona	Positive 4000 V -500 V 2000 V 0 nA		Set Nebulizer Set Dry Heater Set Dry Gas Set Divert Valve Set APCI Heater	0.3 Bar 240 °C 4.0 l/min Source 0 °C
Intens. x10 ⁷						
1./5						
1.70		a start and a start and a start				
1.65				******	*****	
1.60						*******
·	05 0.10	0.15 0.20	0.25	0.30	0.35 (0.40 Time [min]

+MS, 0.0-0.5min #1-27



mk27.d Bruker Compass DataAnalysis 4.3

printed: 2/17/2017 12:13:58 PM

by: KM

Page 1 of 1

Figure S15 (d): HR-MS spectrum of 8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-5,8quinolinedione (**27**).



Figure S16 (a): ¹H-NMR spectrum of 8-octen-6,10-diynyl-1,4-8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-2-methyl-5,8-quinolinedione (28).



Figure S16 (b): ¹³C-NMR spectrum of 8-octen-6,10-diynyl-1,4-8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-2-methyl-5,8-quinolinedione (28).



Figure S16 (c): IR spectrum of 8-octen-6,10-diynyl-1,4-8-octen-6,10-diynyl-1,4-dioxocyclododeca[2,3-g]-2-methyl-5,8-quinolinedione (28).

Analysis Info				Acquisition	Date 2/17/201	17 12:08:53 PM	
Analysis Name Method Sample Name Comment	D:\Data\mk28.d low_mass.m TM Low concentration	I		Operator Instrument	KM impact II	1825265.10082	
Acquisition Par	rameter						
Source Type Focus Scan Begin Scan End	ESI Active 100 m/z 1000 m/z	lon Polarity Set Capillary Set End Plate Offs Set Charging Volta Set Corona	Positive 4000 V et -500 V ige 2000 V 0 nA	S S S S S	et Nebulizer et Dry Heater et Dry Gas et Divert Valve et APCI Heater	0.3 Bar 240 °C 4.0 l/min Source 0 °C	
Intens. x10 ⁷							
2.036-							
2.034-							
2.032							
2.030 0.	05 0.10	0.15 0.20	0.25	0.30 0	.35 0.40	Time [min]	

+MS, 0.0-0.4min #2-25

mk28.d

Bruker Compass DataAnalysis 4.3





printed: 2/17/2017 12:15:47 PM

dioxocyclododeca[2,3-g]-2-methyl-5,8-quinolinedione (28).

by: KM

Page 1 of 1